# What “not FDA-approved” means for compounded semaglutide

The distinction applies to the finished preparation. What FDA has reviewed, what it has not, and why the individual medical reason matters.

Canonical: https://velri.co/blog/compounded-semaglutide-not-fda-approved-label-first-time-mom
Publisher: Velri (https://velri.co/about)
Published: 2026-07-20
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Compounded semaglutide has not gone through FDA review as a finished drug product. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. That is what the “not FDA-approved” disclosure means. [1]

## The ingredient name is only part of the product

A finished medication includes more than its active ingredient. Its formulation, concentration, preparation and labeling affect what a person receives.

FDA has reported concerns with compounded semaglutide that include dosing errors, fraudulent labels and products arriving without adequate refrigeration. It has also warned that semaglutide salt forms are different active ingredients from those used in approved drugs and that the agency is not aware of a lawful basis for their use in compounding. [2]

The prescriber and pharmacist should therefore be discussing the actual preparation, rather than relying on the ingredient name alone.

## Compounding needs a medical basis

FDA says compounded drugs should be used only when a patient's medical needs cannot be met by an FDA-approved drug. Compounding can address a particular need, but it is not the same pathway as approval of a generic medication. [1][2]

The rules also limit routine copies of commercially available drugs. FDA's April 2026 clarification explains that, where a patient-specific significant difference is the basis under 503A, the prescriber must determine and document that difference for the identified patient. Adding another ingredient does not automatically establish it. [3]

## What a clear explanation should cover

For someone offered compounded semaglutide, the discussion should establish why that preparation is being considered, which pharmacy will dispense it and what the exact label will say. It should also explain who answers questions about the prescription and product after delivery.

FDA encourages patients to contact the compounder or telehealth service about unclear instructions or label information. Reports of measurement errors make that communication particularly relevant when a vial or concentration is unfamiliar. [2]

## Sources
[1] Compounding and the FDA: Questions and Answers | FDA. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
[2] FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
[3] FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support